when administered to hearts in vivo (open-chest preparations) or to isolated perfused hearts, cause a rapid rise in cAMP which precedes the contractile response (Cheung and Williamson, 1965; Drummond et al., 1966; Namm et.al., 1968; Kukovetz et al., 1973 Kukovetz et al., , 1975 Drummond and Hemmings, 1973b) ; similar results have been obtained with rabbit (Schumann et al., 1975) and guinea pig (Dobson et al., 1976) papillary muscle and embryonic chick hearts (Poison et al., 1977) . These studies taken together provide substantial, albeit circumstantial, evidence that cAMP triggers or mediates the positive inotropic effect of CA. Such a role for the cyclic nucleotide is supported by a number of impressive studies which have shown that CA stimulate adenylate cyclase in membrane preparations from hearts of several species with an order of potency that parallels their inotropic potency (Murad et al., 1962; Mayer, 1972; Kaumann and Birnbaumer, 1974; Picken and Jarrott, 1975) ; moreover, stimulation of the enzyme in vitro is inhibited competitively by yS-adrenergic blocking agents. The idea has become widely accepted that the yS-adrenergic receptor is coupled to adenylate cyclase in cardiac cells. The relationship of phosphorylase activation to the contractile response has also been examined extensively. Early studies indicated that increased contractile force appeared with low doses of CA that did not produce significant phosphorylase activation (Mayer et al., 1963; Drummond et al., 1964) ; higher doses increased contractility before phosphorylase activation was measurable (Cheung and Williamson, 1965; Williamson and Jamieson, 1965; 0ye, 1965) . In a number of other studies (Robison et al., 1965; Drummond and Hemmings, 1973b) , phosphorylase activation occurred concomitantly with increased tension, and the two events were closely dose-related (Drummond and Hemmings, 1973b) . Activation of phosphorylase kinase is also facilitated by CA in beating hearts (Drummond et al., 1966; Drummond and Duncan, 1966) ; this occurs rapidly and follows close behind the rise in cAMP. Activation of this enzyme (catalyzed by cAMP-dependent protein kinase), with subsequent conver-146 CIRCULATION RESEARCH VOL. 44, No. 2, FEBRUARY 1979 sion of phosphorylase b to a, mediates CA-induced glycogenolysis. The importance of enhanced glycogenolysis in increased cardiac activity is not clear, however, glycogen stores may remain constant during maximal stimulation of the mechanical activity of the heart (Sobel and Mayer, 1973) .
Not all studies support a direct involvement of cAMP in CA action on the heart, however, some of the discordant data have been previously reviewed (Sobel and Mayer, 1973) . More recently, Benfey (1971) and Benfey and Carotin (1971) reported that phenylephrine (PE) stimulated cardiac contractility but did not increase cAMP in rabbit heart slices and chicken papillary muscle, and they concluded that CA increase contractility without affecting cyclic nucleotide formation. This compound, however, has been shown to activate phosphorylase and increase cAMP in perfused hearts (Drummond and Hemrnings, 1973b; McNeill and Verma, 1973; Osnes and 0ye, 1975) . Evidence exists from studies on perfused hearts (Verma and McNeill, 1976b; Starke, 1972) and on papillary muscle (Schumann et al., 1974; Endoh et al., 1976) that the inotropic effect of PE, particularly in low doses, is mediated through a-receptors which do not involve cAMP. At concentrations above /XM, ^-receptors appear to be activated, and give rise to increased contractile activity and augmented cAMP levels (Endoh et al., 1976) . Benfey et al. (1974) have used another approach to support their contention that cAMP is not involved in the inotropic action of CA. They have reported that, at physiological temperatures, CA receptors for both the inotropic response and cAMP formation in rat and frog hearts have typical fi characteristics, i.e., both responses induced by norepinephrine (NE) were inhibited by propranolol and potentiated by phenoxybenzamine. At lower temperatures, however, receptors mediating contractility assumed a characteristics, i.e., NE-induced contractility was strongly inhibited by phenoxybenzamine, and the inhibitory effect of propranolol was greatly reduced. At these lower temperatures, receptors mediated cAMP formation retained /? characteristics. Several investigators Nickerson, 1976, 1977) contend that adrenergic receptors mediating inotropic and chronotropic effects in hearts of various species are interconvertible with temperature, being predominantly /? at temperatures from 25°C to 37°C and predominantly a at lower temperatures. Adrenergic receptors coupled to adenylate cyclase in membrane preparations of rat, dog, and possibly frog hearts are typically /} (Caron and Lefkowitz, 1974) and are not altered by temperature. Recently, Benfey (1977) has argued against the adrenergic receptor interconversion hypothesis. He found that altering the temperature from 24 °C to 14°C in frog ventricle, or from 31°C to 17°C in rat left ventricle, did not alter the inotropic potency of isoproterenol (INE), EPI, and PE, and did not reduce the potency of propranolol as an EPI antagonist. In addition, Martinez and McNeill (1977) have published extensive studies showing that the inotropic effect of adrenergic amines was typically 0 at 37°C, 22°C, and 17°C. There was no interconversion of receptors, nor was there dissociation of the /^-receptor and cAMP formation. The controversy over interconversion of adrenergic receptors in the heart is likely to continue. In our opinion, studies thus far have not provided compelling evidence that adrenergic actions on the heart can be dissociated from cAMP.
One difficulty in proving that cAMP is involved in regulating cardiac contractility is the failure to produce positive effects when the cyclic nucleotide is applied exogenously. Heart cells are highly impermeable to the substance. Kjekshus et al. (1971) performed experiments in which permeability of the heart to the cyclic nucleotide was presumably increased by adding dimethyl sulfoxide (3%) to the perfusion fluid. cAMP (0.1 mM) then caused significant activation of phosphorylase but did not augment contractility in guinea pig hearts. No evidence was provided that intracellular cAMP was actually increased, however. Several tipophilic analogues have been developed, particularly N 6 ,2'-O-dibutyryl cyclic AMP (DBcAMP), which is considered to cross cellular membranes more readily than the free nucleotide. DBcAMP has been shown to produce a positive inotropic action in papillary muscles (Skelton et al., 1970; Wilkerson et al., 1976) , perfused hearts (Kukovetz and Poch, 1970; Ahren et al., 1971; Drummond and Hemmings, 1973a) , and isolated electrically driven atria (Meinertz et al., 1972 (Meinertz et al., ,1973a (Meinertz et al., , 1973c (Meinertz et al., , 1974 . The compound also produced a positive chronotropic effect in spontaneously beating atria (Drummond and Hemmings, 1973a) and in isolated heart cells in culture (Krause et al., 1970; Ghanbari and McCarl, 1976) . The dibutyryl analogue was taken up by beating rat hearts (Drummond et al., 1974) in extremely small amounts and converted primarily to the N 9 -monobutyryl derivative and traces of cAMP. The former compound, which also possesses cardiostimulatory properties (Meinertz et al., 1973b) , bound to cAMP-binding protein (protein kinase) as effectively as cAMP (Drummond et aL, 1974) . Such findings are generally accepted as evidence favoring a role of cAMP in CA-induced inotropism. It should be emphasized, though, that there are major quantitative differences between the actions of DBcAMP and CA. DBcAMP is several orders of magnitude less potent than CA; its action begins slowly and lasts for long periods of time. This may result from slow uptake and slow conversion to the active N^monobutyryl derivative (Drummond et aL, 1974) .
In addition to its positive inotropic action, DBcAMP has been shown (Meinertz et al., 1975 Kaumann, 1977) to decrease the time to peak tension and relaxation time in cat papillary muscle, and markedly to reduce high KC1 contractures in a manner analogous to CA. On "skinned" (sarcolemma-free) cardiac muscle fibers, cAMP itself has direct relaxant effects (Fabiato and Fabiato, 1975) . These findings provide evidence that not only the positive inotropic actions but also the relaxant effects of CA may be mediated by cAMP.
cAMP has been implicated in the cardiac actions of several other agents, particularly phosphodiesterase (PDE) inhibitors. Papaverine produces a positive inotropic action in a variety of heart preparations. In electrically driven atria, this agent (2-20 fiM) produced a concentration-dependent inotropic response that was not inhibited by propranolol and that was preceded by increased cAMP (Holtzmann et al., 1977) . Similar results have been reported for rabbit (Endoh et al., 1975) and guinea pig (Reinhardt and Schumann, 1976) papillary muscle, and this agent has been reported to potentiate the inotropic action of DBcAMP in ventricular and atrial preparations from guinea pigs and cats , although no inotropic effect was observed in ventricular preparations from animals pretreated with reserpine. Henry et al. (1975) , however, found that papaverine caused increased cAMP and phosphorylase activation in perfused guinea pig hearts but produced no inotropic effect; moreover, it did not potentiate the inotropic action of EPI.
Theophylline, a widely used PDE inhibitor, has inotropic effects on the heart, but it is difficult to explain the actions of this compound solely on the basis of cAMP. In atrial preparations this agent (0.1-2 DIM) produced an increase in cAMP which preceded its inotropic action (Heitmann et al., 1976) . When injected into perfused guinea pig hearts, theophylline produced a modest positive inotropic effect and phosphorylase activation but did not increase cAMP (McNeill et al., 1974; Verma and McNeill, 1976a) . It has been shown that methylxanthines prolong rather than reduce the time to peak tension, and they decrease rather than increase the rate of relaxation (Blinks et al., 1972) ; moreover, they enhance rather than decrease contracture produced by high KC1 ; these effects are contrary to those of CA. Thus the cardiac effects of theophylline are likely independent of changes in cAMP, and most probably reflect an action on the sarcoplasmic reticulum (SR) to increase intracellular [Ca 2+ ].
In spite of all these studies, a cause-and-effect relationship between cAMP and the cardiac actions of CA has not been unequivocally established, and the debate continues. In our opinion, however, the conclusion seems inescapable that the cyclic nucleotide performs a regulatory role in contractility, but its actions may be much more complex than originally expected. In view of the complexities of the action of CA on cardiac contractility, this is not surprising, and in fact it should be expected that cAMP could be dissociated from the mechanical response under some circumstances. There are also technical difficulties in these types of experiments. Under most experimental conditions used, the events being measured occur extremely rapidly, usually within seconds after addition of agonist. Distribution of agonist throughout the tissue, fixation of the tissue, and preparation of extracts thereafter are extremely crucial. Each experimental technique and analytical method has its own finite limits of sensitivity, and these may be critical factors, especially when measuring extremely small changes in any parameter. If cAMP is involved in the cardiac actions of CA, the foregoing studies have provided little insight into the nature of the underlying processes. More recent studies have explored mechanisms whereby the cyclic nucleotide may directly affect the contractile process.
cAMP, Phosphorylation Reactions, and Calcium Movements
It has become attractive to consider that cAMP may mediate alterations in Ca 2+ movements across myocardial membranes, thereby altering contractility (see Entman, 1974) . The heart has an absolute requirement for an extracellular source of this cation, and a Ca 2+ influx occurs during the plateau phase of the action potential (Reuter, 1974a) . It has been amply demonstrated that CA produce an increase in the slow inward Ca 2+ current (Reuter, 1974a, b; Reuter and Scholz, 1977) . Tsien et al. (1972) , using the microelectrode technique in calf Purkinje fibers, have shown that theophylline, N 6monobutyryl cAMP, cAMP, and DBcAMP produced an elevation of the initial plateau level in a manner qualitatively similar to that produced by EPI; this change was attributable to an increase in magnitude of the slow inward Ca 2+ current. In addition, the action potential duration was markedly decreased by these agents; i.e., repolarization was hastened. In a later publication (Tsien, 1973) examining the effects of cAMP applied iontophoretically to Purkinje fibers, the cyclic nucleotide produced a rise in the plateau level of the action potential, a marked decrease in action potential duration, and a slight steepening of pacemaker depolarization. These effects were qualitatively similar to those produced by /?-adrenergic compounds. Other studies have shown that DBcAMP increased the slow inward Ca 2+ current (Reuter, 1974b; Tsien et al., 1972) and ^Ca 2+ uptake (Meinertz et al., 1973a (Meinertz et al., , 1973c . Watanabe and Besch (1974) examined the correlation of tissue cAMP levels with restoration of contractility following administration of INE to guinea pig hearts rendered inexcitable with tetrodotoxin or by depolarization with 22 mM K + , and concluded that cAMP modulates the Ca 2+ influx channels. The evidence is therefore considerable that cAMP may affect electrical events as well as the contractile state by altering Ca 2+ movements. It should be noted, however, that the calculated amount of Ca 2+ entering the myocardial cell during the plateau phase of the action potential is insufficient to produce a maximal contractile response (Langer, 1976) , and so additional processes 148 CIRCULATION RESEARCH VOL. 44, No. 2, FEBRUARY 1979 involving Ca 2+ movements must be available to regulate force development.
It is widely accepted that the physiological and biochemical actions of cAMP are a consequence of protein kinase (PK)-catalyzed phosphorylation of specific cellular proteins, and in the heart such reactions have been implicated in cAMP-mediated alterations in contractility. The mechanism by which cAMP activates PK involves binding of the cyclic nucleotide to a regulatory subunit and dissociation of the holoenzyme complex to yield a free catalytic subunit. An excellent correlation has been found between cAMP levels and the PK activity ratio (-cAMP/+cAMP) in response to EPI and the PDE inhibitor 3-isobutyl-l-methylxanthine Keely, et al., 1975b; Keely and Corbin, 1977) providing decisive evidence for the in vivo involvement of this enzyme in cyclic nucleotide action. Measurement of the PK activity ratio can be complicated, however, by redistribution of free catalytic subunits between soluble and particulate cell fractions (Keely et al., 1975a) . The accurate determination of PK activity ratios is of great importance in evaluating the tissue response to hormones, since it is appreciated that the resulting cellular increment in cAMP may exceed that required for the cellular response. In addition, increases in the PK activity ratio occur (Keely and under conditions in which no elevation of cAMP is observed, suggesting that localized increases in cAMP that are too small to be measured by the standard cAMP assay may be sufficient to activate PK and initiate a biological response. A large fraction of the cAMP in the myocardium is bound to both soluble and particular proteins (Terasaki and Brooker, 1977; ; particulate-bound cAMP is probably associated with the regulatory subunit of PK. Perfusion of hearts with EPI with or without the PDE inhibitor 3-isobutyl-l-methylxanthine resulted in a greater increase of free cAMP than of bound nucleotide, indicating saturation of binding sites on the regulatory subunit (Terasaki and Brooker, 1977; . These findings emphasize the complexities involved in the interpretation of tissue levels of cAMP; such complexities have undoubtedly contributed to the conflicting evidence summarized earlier concerning the involvement of the cyclic nucleotide in the inotropic action of CA. It is important also to emphasize that PK is a nonspecific enzyme which catalyzes the phosphorylation of a wide variety of proteins, membrane-bound as well as soluble. Therefore, results based on demonstration of protein phosphorylation in vitro should be interpreted with caution. A number of other criteria, such as demonstration of reversibility by an appropriate protein phosphatase and phosphorylation induced by hormone in vivo, should be demonstrated before concluding that a PK-catalyzed phosphorylation is a satisfactory explanation for cAMP involvement.
One site phosphorylated by cAMP-dependent PK which has attracted much attention with re-spect to Ca 2+ flux and enhanced contractility resides within the SR. It was observed some years ago (Entman et al., 1968 ) that cAMP stimulated Ca 2 * accumulation in cardiac SR preparations. Later, PK activity intrinsic to cardiac microsomes was reported (Wray et al., 1973) , and phosphorylation of microsomal membranes (fragmented SR) in the presence of cAMP was demonstrated in vitro (Laraia and Morkin, 1974) . The site phosphorylated was a protein of molecular weight about 20,000; an intrinsic phosphoprotein phosphatase was also identified. cAMP-mediated phosphorylation of microsomes caused an increase in the initial rate of Ca 2+ accumulation (measured in the presence of oxalate) (Laraia and Morkin, 1974 ). This phosphorylation system in cardiac microsomes has been extensively studied by Katz and his colleagues Tada et al., 1974 Tada et al., , 1975 . Phosphorylation of microsomes correlated closely with an enhanced rate of Ca 2+ uptake (oxalate-facilitated); there was no effect on Ca 2+ binding (oxalate absent) . Fractionation of phosphorylated membranes by sodium dodecyl sulfate-polyacrylamide electrophoresis showed that a single protein (molecular weight 22,000), which was called phospholamban, was the substrate for PK (Tada et al., 1975) . Incubation of microsomes with EPI also caused phosphorylation, presumably due to stimulation of adenylate cyclase present in the membrane fraction . Oxalate-facilitated Ca 2+ uptake by cardiac microsomes has been characterized kinetically as a slow nonsaturable process (Katz and Repke, 1973) . It would seem doubtful that such a mechanism could be involved in regulating contractility. However, a recent investigation using quench-flow techniques with low concentrations of Ca 2+ has demonstrated a reproducible increase in initial velocity of Ca 2+ binding following incubation of microsomes with PK and cAMP . The presence of a phosphoprotein phosphatase-catalyzed dephosphorylation of microsomes which correlated with a decreased rate of Ca 2+ transport (Kirchberger and Raffo, 1977) , suggests a mechanism for reversal of this process. Katz and his colleagues have proposed the microsomal phosphorylation system as a mechanism whereby CA accelerate cardiac relaxation. Thus, following cAMP formation by stimulation of adenylate cyclase, PK-dependent phosphorylation of phospholamban would occur; this would lead to enhanced Ca 2+ transport into the SR, causing accelerated relaxation and, consequently, abbreviation of systole. They also suggest that the increased amount of Ca 2+ sequestered in the SR could be released during the subsequent beat, thus producing enhanced force of contraction and increased rate of tension development. Evidence in favor of this scheme has been provided by Rolett (1974) , who observed that the initial mechanical response of the heart to NE was decreased duration of systole, followed later by a rise in tension.
Another possible site of phosphorylation is the CYCLIC NUCLEOTIDES AND CARDIAC FUNCTION/Drummwui and Severson 149 contractile proteins. Phosphorylation of canine cardiac tropomyosin has been observed following the addition of cAMP (Reddy et al., 1973) . Fractionation of native tropomyosin demonstrated that phosphorylation (exogenous PK) was restricted to the troponin complex; tropomyosin itself was not phosphorylated. Cardiac troponin is composed of three distinct subunits (Brekke and Greaser, 1976) : TN-I, which inhibits actomyosin ATPase activity; TN-T, which binds tightly to tropomyosin; and TN-C, which binds Ca 2+ . Two recent studies (Cole and Perry, 1975; Stull and Buss, 1977) have shown that the TN-I component is the main site of phosphorylation, with a maximal incorporation of 1 mole of phosphate per mole of protein. Incubation of cardiac troponin or the troponin-tropomyosin complex with cAMP and PK caused a rapid rate of phosphorylation which was independent of the endogenous phosphate content of the complex . It would be logical to consider that phosphorylated troponin might possess an altered affinity for Ca 2+ in a manner analogous to the differences in Ca 2+ affinity for nonactivated and activated (phosphorylated) phosphorylase b kinase (Brostrom et al., 1971 ). However, the recent studies of Buss and Stull (1977) clearly indicate that phosphorylation of cardiac troponin-tropomyosin by cAMP-dependent PK does not alter the affinity for Ca 2+ or the amount of cation bound. In addition, the affinity or capacity for Ca 2+ binding was not different in preparations of troponin-tropomyosin containing variable quantities of endogenous protein-bound phosphate .
The possibility of a correlation between contraction and phosphorylation of TN-I has been examined in isolated rat hearts (England, 1975 (England, , 1976 . Perfusion with EPI or INE resulted in an increase in TN-I phosphorylation that closely paralleled the increase in contractile force (England, 1975 (England, , 1976 ; dose-response curves for incorporation of ^P into troponin and increased contractile tension were superimposable. Plotting the data from time-course and dose-response curves revealed a linear correlation between increased contractile force and TN-I phosphorylation up to 1 mole of phosphate per mole of troponin. Not all experiments were consistent, however, with a close correlation between TN-I phosphorylation and contractile force; studies with pulse perfusion of rat hearts using submaximal doses of INE showed that phosphorylation of TN-I remained elevated at a time when contractile force had returned to control values. Similarly, pulse perfusion with INE followed by continuous perfusion with acetylcholine resulted in diminished contractile force that preceded the dephosphorylation of TN-I (England, 1976) . A mechanism whereby phosphorylation of troponin could lead to an increase in force of contraction has not yet been established; it does not seem to involve Ca 2+ binding. Positive inotropic responses induced by ouabain, increased frequency of stimulation, and addition of ionophore, or Ca 2+ were not associated with phosphorylation of TN-I (Ezrailson et al., 1977) , suggesting that only those agents which elevate cAMP result in the incorporation of phosphate into TN-I.
In view of the importance of inward Ca 2+ movement across the sarcolemma (SL) in mediating electrical events and in providing a source of this cation to support contractility, the SL has been considered a likely site for cAMP-facilitated phosphorylation. Such studies have been hampered by an inability to isolate completely pure plasma membranes from cardiac tissue. Recently, however, Hui et al. (1976) and Sulakhe et al. (1976) have reported studies on PK-catalyzed phosphorylation of plasma membranes isolated from guinea pig ventricle. A cAMPdependent phosphorylation due to endogenous PK was observed (Hui et al., 1976; Sulakhe et al., 1976) . Reversiblity of membrane phosphorylation, presumably due to phospoprotein phosphatase activity, was also demonstrated (Hui et al., 1976) . The SL membranes bound Ca 2+ in an ATP-dependent manner; addition of oxalate (in the presence of ATP) resulted in Ca 2+ accumulation. Phosphorylated membranes accumulated more Ca 2+ than did control preparations. EPI caused enhanced phosphorylation and increased the rate of Ca 2+ uptake (Sulakhe et al., 1976) . Although this is a model system, the data suggest the possibility that cAMP may be involved in transsarcolemmal Ca 2+ flux via a reversible phosphorylation-dephosphorylation process involving cAMP-dependent PK and phosphoprotein phosphatase. Recently a similar cAMPmediated phosphorylation-dephosphorylation system with altered Ca 2+ flux has been proposed to explain the chronotropic action of CA on cardiac pacemaker cells (Pollack, 1977) .
The foregoing studies create the possibility that, in the presence of CA, several membrane sites may be phosphorylated, with a common end result-altered Ca 2+ fluxes. By such a "multi-site" phosphorylation mechanism, the cyclic nucleotide might initiate several of the actions of CA, both electrical and mechanical. This is consistent with the fact that a portion of the cAMP-dependent PK, as well as the cyclic nucleotide itself, is membranebound (Terasaki and Brooker, 1977; . We are still a long way, however, from knowing whether such phosphorylation-dephosphorylation reactions could function in vivo so as to modulate contractility on a beat-to-beat basis, and at present they should be looked upon largely as model systems upon which to base more incisive physiological experiments.
cGMP and Cardiac Function
The possibility that cGMP may have regulatory actions on the heart antagonistic to those of cAMP has been actively pursued in recent years. Early studies showed that perfusion of rat hearts with acetylcholine (ACh) produced elevated cGMP levels that correlated with decreased contractile force and rate (George et al., 1970 (George et al., , 1973 ; cAMP levels were decreased by ACh, but this did not correlate with changes in contractile activity 150 CIRCULATION RESEARCH VOL. 44, No. 2, FEBRUARY 1979 (George et al., 1973) . ACh increased cGMP and decreased contractile force in electrically driven hearts as well. Further studies using isolated paced rabbit atria and in situ rabbit right atrium-vagus nerve preparations suggested that increased cGMP produced by ACh or by vagal stimulation was associated with decreased contractile tension (Fink et al., 1976; George et al., 1975) . However, Diamond et al. (1977) have recently reported that low concentrations (0.05 JIM) of ACh decreased atrial twitch tension without changing cGMP levels; sodium nitroprusside markedly increased cGMP but did not affect tension. Similarly, Watanabe and Besch (1975) found that although ACh markedly elevated cGMP, no change occurred in the contractile state in guinea pig ventricles. This same dose of ACh decreased the inotropic response to INE without resulting in a decrease in cAMP. The authors suggested that cGMP may mediate the antiadrenergic effects of ACh by specifically antagonizing the inotropic actions of cAMP. Effects of ACh on cyclic nucleotide levels have also been investigated in myocardial slice preparations (Lee et al., 1971 (Lee et al., , 1972 . ACh antagonized the rise in cAMP due to INE in rat and calf heart slices (Lee et al., 1971) . ACh and other muscarinic agents increased the myocardial content of cGMP; this effect was blocked by atropine (Lee et al., 1972) . Krause et al. (1972) have shown that dibutyryl cGMP exerted a negative chronotropic action on isolated cultured heart cells of rats; in addition, the positive chronotropic effect of EPI in such preparations was antagonized by dibutyryl cGMP. Dibutyryl cGMP was found (Watanabe and Besch, 1975) to antagonize the positive inotropic effect of INE on perfused guinea pig hearts. A concentration-dependent negative inotropic effect of 8-bromo cGMP has been reported in paced or spontaneously beating atria; no effect of the 8-bromo derivative on the rate of spontaneously beating atria was observed (Nawrath, 1976 ).
Regulation of cyclic nucleotide levels and glycogen phosphorylase activity by ACh has been examined in perfused rat hearts Allen, 1976a, 1976b) . ACh caused a time-and dose-dependent increase in cGMP with no change in cAMP or phosphorylase activity; EPI produced a typical increase in cAMP and phosphorylase activation with no change in cGMP. The addition of ACh to hearts perfused with EPI resulted in a time-dependent increase in cGMP and a decrease in cAMP; both changes in cyclic nucleotides preceded a significant decrease in phosphorylase a activity (Lee et al., 1971; Gardner and Allen, 1976b ). Recent investigations have suggested that the inhibitory action of ACh on EPI-stimulated phosphorylase activity was the result of decreased cAMP (Gardner and Allen, 1977) ; the role of cGMP in this metabolic effect of ACh remains to be clarified.
At present, a molecular mechanism to explain the postulated effects of cGMP on myocardial me-tabolism or contractility has not been established. Presumably, effects of cGMP will be mediated by a cGMP-dependent PK-catalyzed phosphorylation. Gill et al. (1977) have recently purified to homogeneity a cGMP-dependent PK, and it has been reported (Blumenthal et al., 1978) that this kinase phosphorylates TN-I in a manner analogous to the cAMP-dependent enzyme. This finding is difficult to reconcile with the hypothesis that cAMP and cGMP have opposing actions in the myocardial cell; however, kinetic considerations actually suggested that little or no cGMP-dependent phosphorylation would occur in vivo (Blumenthal et al., 1978) . At this time, the possibility that cGMP mediates cholinergic input to the heart or antagonizes the effect of CA by opposing the actions of cAMP is very unsettled, and no definitive role of this cyclic nucleotide in cardiac function is yet apparent. 
